Burning Rock Biotech Limited (NASDAQ: BNR) kicked off on June 21, 2022, at the price of $2.13, up 8.63% from the previous trading day. During the day, the shares moved up to $2.30 and dropped to $2.10 before settling in for the closing price of $1.97. Over the past 52 weeks, BNR has traded in a range of $1.74-$30.50.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free.
While this was happening, its average annual earnings per share was recorded -11.20%. With a float of $71.55 million, this company’s outstanding shares have now reached $104.50 million.
Let’s look at the performance matrix of the company that is accounted for 938 employees. In terms of profitability, gross margin is +71.70, operating margin of -156.94, and the pretax margin is -156.70.
Burning Rock Biotech Limited (BNR) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Diagnostics & Research Industry. The insider ownership of Burning Rock Biotech Limited is 5.83%, while institutional ownership is 64.10%.
Burning Rock Biotech Limited (BNR) Performance Highlights and Predictions
In the latest quarterly report, which was put into the public domain on 12/30/2021, the organization reported -$0.36 earnings per share (EPS), lower than consensus estimate (set at -$0.25) by -$0.11. This company achieved a net margin of -156.87 while generating a return on equity of -37.45. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.36 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -11.20% per share during the next fiscal year.
Burning Rock Biotech Limited (NASDAQ: BNR) Trading Performance Indicators
Take a look at Burning Rock Biotech Limited’s (BNR) current performance indicators. Last quarter, stock had a quick ratio of 3.90. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.83.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.27, a number that is poised to hit -2.40 in the next quarter and is forecasted to reach -4.29 in one year’s time.
Technical Analysis of Burning Rock Biotech Limited (BNR)
Burning Rock Biotech Limited (NASDAQ: BNR) saw its 5-day average volume 2.38 million, a positive change from its year-to-date volume of 0.43 million. As of the previous 9 days, the stock’s Stochastic %D was 42.16%. Additionally, its Average True Range was 0.25.
During the past 100 days, Burning Rock Biotech Limited’s (BNR) raw stochastic average was set at 4.20%, which indicates a significant decrease from 51.95% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 91.09% in the past 14 days, which was lower than the 96.19% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $4.1800, while its 200-day Moving Average is $10.2200. Nevertheless, the first resistance level for the watch stands at $2.2600 in the near term. At $2.3800, the stock is likely to face the second major resistance level. The third major resistance level sits at $2.4600. If the price goes on to break the first support level at $2.0600, it is likely to go to the next support level at $1.9800. Assuming the price breaks the second support level, the third support level stands at $1.8600.
Burning Rock Biotech Limited (NASDAQ: BNR) Key Stats
The company with the Market Capitalisation of 226.28 million has total of 105,109K Shares Outstanding. Its annual sales at the moment are 79,690 K in contrast with the sum of -125,020 K annual income. Company’s last quarter sales were recorded 21,380 K and last quarter income was -41,230 K.